Research news

A clinical trial at UCLH is investigating whether adding a targeted cancer drug called adagrasib to standard first-line immunotherapy and chemotherapy can delay disease progression in people with advanced non-small cell lung cancer (NSCLC) – the most common type of lung cancer.

UCLH have recruited the first participant in the world to a new global phase I study for early Alzheimer’s Disease (AD).

UCLH is accelerating clinical trial delivery so that patients gain access to new treatments sooner. The acceleration is happening through close collaboration between research teams and clinical services.

UCLH consultant urological surgeon Veeru Kasivisvanathan has been awarded the prestigious Society of Apothecaries’ 2026 William Farr Medal in recognition of his work to advance prostate cancer care globally.

There are now seven patients participating in the GB-PRIME study involving Neuralink’s brain-computer interface (BCI) technology, which aims to improve independence for people who are paralysed.